Johnson & Johnson
Campaign highlights low expectations among patients with depression
May 7, 2026Johnson & Johnson, major depressive disorder (MDD)
A new global awareness campaign from Johnson & Johnson is aiming to encourage people with major depressive disorder (MDD) to …
Johnson & Johnson submits robotic surgical system for De Novo classification
January 8, 2026Research and Development FDA, Gastrointestinal tract, Johnson & Johnson
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De Novo classification from the US …
Johnson & Johnson commits $2bn to new manufacturing facility in North Carolina, US
August 22, 2025Manufacturing and Production Corporate, Fujifilm, Johnson & Johnson
Johnson & Johnson has announced a $2bn investment in a new manufacturing facility in Holly Springs, North Carolina, US, expanding …
Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse
July 18, 2025Medical Communications, Research and Development CAPLYTA, Johnson & Johnson, Neurology, US Food and Drug Administration, neuroscience, new drug application, schizophrenia
Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Caplyta …
Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment
July 4, 2025Medical Communications, Research and Development European Medicines Agency, Genito-Urinary system, Johnson & Johnson, Oncology, clinical trial, prostate cancer
Johnson & Johnson has submitted an application to the European Medicines Agency for an indication extension of Akeega (niraparib and …
Nanoform receives €5m loan from Finnish government to accelerate its nanotechnology
June 20, 2025Freelancers, Licensing & business development, Research and Development Devices, Johnson & Johnson, Nanoform Finland, Oncology, amorphous solid dispersion technology, government loan, nanoparticle medicine, nanotechnology, prostate cancer
Nanoform Finland [Nanoform], a leading nanoparticle medicine company, is pleased to announce that Business Finland has approved a €5m research …
Johnson & Johnson presents promising data on leukaemia treatment
June 16, 2025Medical Communications, Research and Development European Hematology Association, Janssen-Cilag, Johnson & Johnson, Oncology, chronic lymphocytic leukaemia, clinical trial
Janssen-Cilag, a Johnson & Johnson company, has announced results from a matching-adjusted indirect comparison presented at this year’s European Hematology …
European Commission approves Johnson & Johnson’s Crohn’s disease therapy
May 12, 2025Market Access, Research and Development, Sales and Marketing Crohn’s disease, European Commission, Gastrointestinal tract, Johnson & Johnson, guselkumab, marketing authorisation
The European Commission (EC) has granted Marketing Authorisation (MA) to Johnson & Johnson’s Tremfya (guselkumab) for the treatment of moderately …
Majority of Europeans trust technology to improve healthcare, Johnson & Johnson survey finds
May 8, 2025Research and Development AI, Corporate, Devices, EU Data Act, HCPs, Johnson & Johnson, Pharmacy, digital technology, survey
A global survey by Johnson & Johnson MedTech has revealed that a majority of Europeans are willing to share their …
Johnson & Johnson announces successful results from trial for myeloma treatment
April 16, 2025Research and Development Johnson & Johnson, Oncology, myeloma, pharma, trial
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed significantly longer progression-free survival (PFS) …
J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression
July 24, 2024Medical Communications J&J, Johnson & Johnson, Neurology, Spravato, treatment-resistant depression
Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application (sNDA) to the US Food …
J&J’s Tremfya meets primary and secondary endpoints in UC maintenance study
May 21, 2024Medical Communications Gastrointestinal tract, J&J, Johnson & Johnson, clinical trial, ulcerative colitis
Johnson & Johnson (J&J) has announced the first data from its phase 3 QUASAR maintenance study which assessed Tremfya (guselkumab) …
Johnson & Johnson to acquire Shockwave Medical
April 8, 2024Business Services Cardiology, Johnson & Johnson, Shockwave Medical, acquisition
Johnson & Johnson (J&J) and Shockwave Medical have announced that they have entered into a definitive agreement under which J&J …
FDA approves J&J’s Opsynvi for PAH treatment
March 25, 2024Medical Communications Cardiology, FDA, J&J, Johnson & Johnson, Opsynvi, pulmonary arterial hypertension
Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has approved Opsynvi (macitentan and tadalafil) …
Johnson & Johnson acquires Ambrx Biopharma for approximately $2bn
March 11, 2024Business Services ADCs, Ambrx Biopharma, J&J, Johnson & Johnson, Oncology, acquisition
Johnson & Johnson (J&J) has announced that it has successfully completed its acquisition of Ambrx Biopharma in an all-cash merger …
